A detailed history of Wells Fargo & Company transactions in Rallybio Corp stock. As of the latest transaction made, Wells Fargo & Company holds 50,300 shares of RLYB stock, worth $49,294. This represents 0.0% of its overall portfolio holdings.

Number of Shares
50,300
Previous 37,800 33.07%
Holding current value
$49,294
Previous $50,000 16.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$1.09 - $1.45 $13,625 - $18,125
12,500 Added 33.07%
50,300 $58,000
Q2 2024

Aug 13, 2024

BUY
$1.34 - $2.98 $15,791 - $35,119
11,785 Added 45.3%
37,800 $50,000
Q1 2024

May 10, 2024

BUY
$1.25 - $2.4 $20,482 - $39,326
16,386 Added 170.17%
26,015 $48,000
Q4 2023

Feb 09, 2024

BUY
$1.91 - $4.39 $3,541 - $8,139
1,854 Added 23.85%
9,629 $23,000
Q3 2023

Nov 13, 2023

SELL
$3.37 - $6.16 $13,793 - $25,212
-4,093 Reduced 34.49%
7,775 $26,000
Q2 2023

Aug 15, 2023

BUY
$4.31 - $8.89 $34,436 - $71,031
7,990 Added 206.03%
11,868 $67,000
Q1 2023

May 12, 2023

BUY
$4.37 - $8.75 $15,635 - $31,307
3,578 Added 1192.67%
3,878 $22,000
Q4 2022

Feb 13, 2023

SELL
$4.67 - $14.86 $1,046 - $3,328
-224 Reduced 42.75%
300 $1,000
Q3 2022

Nov 14, 2022

SELL
$7.54 - $14.56 $821 - $1,587
-109 Reduced 17.22%
524 $7,000
Q2 2022

Aug 12, 2022

SELL
$6.26 - $13.65 $18,992 - $41,414
-3,034 Reduced 82.74%
633 $5,000
Q1 2022

May 16, 2022

SELL
$6.91 - $15.04 $1,582 - $3,444
-229 Reduced 5.88%
3,667 $26,000
Q4 2021

Feb 14, 2022

BUY
$9.3 - $19.91 $35,870 - $76,792
3,857 Added 9889.74%
3,896 $37,000
Q3 2021

Nov 15, 2021

BUY
$10.83 - $23.4 $422 - $912
39 New
39 $1,000

Others Institutions Holding RLYB

About Rallybio Corp


  • Ticker RLYB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,132,000
  • Market Cap $31.5M
  • Description
  • Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of feta...
More about RLYB
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.